Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa

Hepatology

Volumn 24, Issue 1, 1996, Pages 6-9

  Cacciarelli, Thomas V ^a   Martinez, Olivia M ^a,b   Gish, Robert G ^a   Villanueva, Janeth C ^a,b   Krams, Sheri M ^a,b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS DETECTION;

EID: 0029949897     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008707283     Document Type: Article

References (32)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Ya Hu P, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
2. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
3. Cherwinski HC, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone: 3. Further differences in lymphokine synthesis between TH1 and TH2 clones revealed by RNA hybridization, functionally monospecific bioassays and monoclonal antibodies. J Exp Med 1987;166: 1229-1244.
4. Nathan CF, Murray HW, Weibe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983;158:670-689.
5. Spits H, Yssel H, Paliard X, Kastelein R, Figdor C, de Vries JE. IL-4 inhibits IL-2 mediated induction of human lymphokine-activated killer cells, but not generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 1988;141:29-36.
6. Kern DE, Gillis S, Okada M, Henney CS. The role of interleukin 2 (IL-2) in the differentiation of cytotoxic T cells: the effect of monoclonal anti-IL-2 antibody and adsorption with IL-2 dependent T cell lines. J Immunol 1981;127:1323-1328.
7. Aoki T, Kikuchi H, Miyatake SI, Oda Y, Iwasaki K, Yamasaki T, Kinashi T, et al. Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity. J Exp Med 1989;170:583-588.
8. Balkwill FR, Burke F. The cytokine network. Immunol Today 1989;10: 299-304.
9. Daniels HM, Meager A, Eddleston AL, Alexander GJ, Williams R. Spontaneous production of tumour necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet 1990; 335:875-877.
10. Anastassakos C, Alexander GJ, Wolstencroft RA, Avery JA, Portmann BC, Panayi GS, Dumonde DC, et al. Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology 1988;94:999-1005.
11. Civeira M, Prieto J, Morte S, Rinon M, Serrano M. Interleukins in chronic active hepatitis B: relationship with viral markers. J Hepatol 1987;5:37-44.
12. Minuk GY, LaFreniere R. Interleukin-1 and interleukin-2 in chronic type B hepatitis. Gastroenterology 1988;94:1094-1096.
13. Kakumu S, Fuji A, Yoshioka K, Tahara H. Serum levels of alpha-interferon and gamma-interferon in patients with acute and chronic viral hepatitis. Hepatogastroenterology 1989;36:97-102.
14. Ikeda T, Lever AML, Thonas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. HEPATOLOGY 1986;6:962-965.
15. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
16. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. HEPATOLOGY 1995;21:291-297.
17. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-883.
18. Alexander GJ, Nouri-Aria KT, Nueberger J, Bakhtiar M, Vogel W, Anderson MG, Magrin S, et al. In vitro effects of lymphoblastoid interferon on lymphocyte activation and cell-mediated cytolysis in patients with chronic hepatitis B virus infection. J Hepatol 1986;3(suppl 2):S269-S277.
19. Bianchi L, de Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, et al. Acute and chronic hepatitis revisited: review by an international group. Lancet 1977;2:914-919.
20. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
21. Martinez OM, Villanueva JC, Lawrence-Miyasaki L, Quinn MB, Cox K, Krams SM. Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation 1995;59:519-524.
22. Choo QL, Kuo G, Wecner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:362-374.
23. Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R, Marullo S. Quantitative analysis of transforming growth factor β1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. HEPATOLOGY 1995;21:298-304.
24. Yamashiki M, Nishimura A, Takase K, Nakano T, Kosaka Y. Effects of the streptococcal preparation OK-432 on in vitro cytokine production of peripheral blood mononuclear cells in patients with chronic viral hepatitis. J Clin Lab Immunol 1992;38:73-82.
25. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103:264-274.
26. Nagler A, Lanier LL, Phillips JH. The effects of IL-4 on human natural killer cells. A potent regulator of IL-2 activation and proliferation. J Immunol 1988;141:2349-2351.
27. Martinez OM, Gibbons RS, Garovoy MR, Aronson FR. IL-4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. J Immunol 1990;144:2211-2215.
28. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-924.
29. Florentine DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-3451.
30. Onji M, Lever AM, Saito I, Thomas HC. Defective response to interferons in cells transfected with the hepatitis B virus genome. HEPATOLOGY 1989; 9:92-96.
31. Ikeda T, Lever AM, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. HEPATOLOGY 1986;6:962-965.
32. Davis GL, Hoofnagle JH. Interferon in viral hepatitis: role in pathogenesis and treatment. HEPATOLOGY 1986;6:1038-1041.